Published Articles

The following articles detail some of our extensive experience with various intellectual property issues:

US: The Year in Review
Pharmaceutical Law Insight, December 2008/January 2009
To Read the Complete Newsletter, Click here.

Supreme Court Unanimously Tightens the Test for Patentability
Orthopedic Design & Technology, July, 2007

Got a Cease-and-Desist Letter? Call Your Patent Attorney Today
Orthopedic Design & Technology, May 2007

Around the World in Two Stages: Protect Your Invention Globally
Orthopedic Design & Technology, March 2007

Non-disclosure Pacts: An Ounce of Prevention
Orthopedic Design & Technology, January 2007

Media Coverage

Our attorneys are frequently called upon by the media to serve as resources for commentary on a range of intellectual property issues:

Patent World
November 2008

In the Patent World article, “US Presidential Candidates Back Biosimilars,” Joseph Trojan forecasts that even with the four biosimilar bills currently before Congress, nothing will progress in 2008 and they will likely be reintroduced later in 2009, with a bill in place by 2010.  Mr. Trojan went on to comment that the biosimilars proposition related to clinical testing of biosimilar drugs is unlikely to make it into a final bill, but a diluted version would pass.

Los Angeles Business Journal
October 20, 2008

Joseph Trojan was quoted in the Los Angeles Business Journal article, “HIV, AIDS Developer Heads to Court in Company Feud.”  The article examines the lawsuit brought by biotech company Viral Genetics Inc. against its former executive who is accused of attempting to bankrupt the company and taking intellectual property to another firm.  Based on the complaint, Mr. Trojan said that the allegations were shocking if true.

Announcements

February 9, 2009

PHOENIX LICENSES WELLS FARGO BANK, N.A. TO PATENTS COVERING USE OF INTERACTIVE VOICE RESPONSE SYSTEMS

Phoenix Solutions, Inc. has licensed its speech recognition/Advanced language processing portfolio covering Interactive Voice Response (IVR) systems to Wells Fargo Bank, N.A. for the latters use of such technology in responding to call queries concerning customer accounts and other related applications. The portfolio encompasses numerous technologies in wide spread use in the IVR industry, and includes some 300+ issued claims in United States Patent Nos. 6,615,172; 6,633,846; 6,665, 640; 7,050,977; 7,139,714; 7,225,125; 7,277,854; 7,203,646; 7,376,566, 7,392,185 as well as several hundred additional claims pending in more than 2 dozen domestic and foreign applications. The parties have further agreed to dismiss the pending litigation in the Northern District of California as well. Other terms of the license were kept confidential.

For information on how to secure a license to the Phoenix portfolio, please contact Mr. R. Joseph Trojan of Trojan Law Offices in Beverly Hills, CA (310) 777 8399.

November 17, 2008

PHOENIX LICENSES TICKETMASTER TO PATENTS COVERING USE OF INTERACTIVE VOICE RESPONSE SYSTEMS

LOS ANGELES – Phoenix Solutions, Inc. has licensed its speech recognition/Advanced language processing portfolio covering Interactive Voice Response (IVR) systems to Ticketmaster for the latter’s use of such technology in responding to call queries concerning entertainment events. The portfolio encompasses numerous technologies in wide spread use in the IVR industry, and includes some 300+ issued claims in United States Patent Nos. 6,615,172; 6,633,846; 6,665, 640; 7,050,977; 7,139,714; 7,225,125; 7,277,854; 7,203,646; 7,376,566 as well as several hundred additional claims pending in more than 2 dozen domestic and foreign applications. Other terms of the license were kept confidential.

For information on how to secure a license to the Phoenix portfolio, please contact Mr. R. Joseph Trojan of Trojan Law Offices in Beverly Hills, CA (310) 777 8399.

November 4, 2008

TROJAN LAW OFFICES OBTAINS PATENT APPROVAL FOR FETUIN DERIVED POLYPEPTIDE TO TREAT CANCER

LOS ANGELES – Trojan Law Offices, an intellectual property law firm with expertise in biomedical sciences announces the issuance of United States Patent No. 7,445,784 for “Polypeptide For The Treatment of Cancer And a Method For Preparation Thereof” on behalf of its client, Ambryx Biotechnology, Inc.

“It’s rewarding to see Ambryx obtain yet another patent for its significant discoveries in the treatment of cancer,” commented lead patent counsel, R. Joseph Trojan.  “The apoptotic activity of this fetuin derived polypeptide is significant because of its targeted effect on cancer cells, which basically means that it re-programs cancer cells so that they die without harming surrounding cells.”

Ambryx Biotechnology Inc. is a privately-held biomedical company that discovers naturally occurring bioactive peptides which can be used to develop safe and effective therapeutic drug treatment products to be used in cancer and obesity treatment programs.